Design and Application of pH-Responsive Liposomes for Site-Specific Delivery of Cytotoxin from Cobra Venom

References

• Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 2021;141(1):23–31. doi:10.1016/j.jid.2020.03.943
   PubMed Web of Science ®Google Scholar
• Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495–503. doi:10.1001/jamadermatol.2022.0160
   PubMed Web of Science ®Google Scholar
• Marin-Bejar O, Rogiers A, Dewaele M, et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell. 2021;39(8):1135–1149.e1138. doi:10.1016/j.ccell.2021.05.015
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted therapy in melanoma and mechanisms of resistance. Int J Mol Sci. 2020;21(13):4576. doi:10.3390/ijms21134576
   PubMed Web of Science ®Google Scholar
• Liu CC, Wu CJ, Chou TY, et al. Development of a monoclonal scFv against cytotoxin to neutralize cytolytic activity induced by naja atra venom on myoblast C2C12 cells. Toxins. 2022;14(7):459. doi:10.3390/toxins14070459
   PubMed Web of Science ®Google Scholar
• Beraldo E, Coelho GR, Sciani JM, Pimenta DC. Proteomic characterization of Naja mandalayensis venom. J Venom Anim Toxins Incl Trop Dis. 2021;27:e20200125 doi:10.1590/1678-9199-JVATITD-2020-0125
   PubMed Web of Science ®Google Scholar
• Dubovskii PV, Efremov RG. The role of hydrophobic /hydrophilic balance in the activity of structurally flexible vs. rigid cytolytic polypeptides and analogs developed on their basis. Expert Rev Proteom. 2018;15(11):873–886. doi:10.1080/14789450.2018.1537786
   PubMed Web of Science ®Google Scholar
• Dubovskii PV, Dubova KM, Bourenkov G, et al. Variability in the spatial structure of the central loop in cobra cytotoxins revealed by X-ray analysis and molecular modeling. Toxins. 2022;14(2):149. doi:10.3390/toxins14020149
   PubMed Web of Science ®Google Scholar
• Li F, Shrivastava IH, Hanlon P, Dagda RK, Gasanoff ES. Molecular mechanism by which cobra venom cardiotoxins interact with the outer mitochondrial membrane. Toxins. 2020;12(7):425. doi:10.3390/toxins12070425
   PubMed Web of Science ®Google Scholar
• Hiu JJ, Yap MKK. The effects of Naja sumatrana venom cytotoxin, sumaCTX on alteration of the secretome in MCF-7 breast cancer cells following membrane permeabilization. Int J Biol Macromol. 2021;184:776–786. doi:10.1016/j.ijbiomac.2021.06.145
   PubMed Web of Science ®Google Scholar
• Liu Y, Ming W, Wang Y, et al. Cytotoxin 1 from Naja atra Cantor venom induced necroptosis of leukemia cells. Toxicon. 2019;165:110–115. doi:10.1016/j.toxicon.2019.04.012
   PubMed Web of Science ®Google Scholar
• Abdel-Ghani LM, Rahmy TR, Tawfik MM, et al. Cytotoxicity of Nubein6.8 peptide isolated from the snake venom of Naja nubiae on melanoma and ovarian carcinoma cell lines. Toxicon. 2019;168:22–31. doi:10.1016/j.toxicon.2019.06.220
   PubMed Web of Science ®Google Scholar
• Derakhshani A, Silvestris N, Hajiasgharzadeh K, et al. Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: a potential treatment for breast cancer. Int J Biol Macromol. 2020;162:1283–1292. doi:10.1016/j.ijbiomac.2020.06.130
   PubMed Web of Science ®Google Scholar
• Chong HP, Tan KY, Tan CH. Cytotoxicity of snake venoms and cytotoxins from two southeast asian cobras (Naja sumatrana, Naja kaouthia): exploration of anticancer potential, selectivity, and cell death mechanism. Front Mol Biosci. 2020;7:583587. doi:10.3389/fmolb.2020.583587
   PubMed Web of Science ®Google Scholar
• Wong KY, Tan KY, Tan NH, Tan CH. A neurotoxic snake venom without phospholipase A(2): proteomics and cross-neutralization of the venom from senegalese cobra, naja senegalensis (Subgenus: uraeus). Toxins. 2021;13(1):60. doi:10.3390/toxins13010060
   PubMed Web of Science ®Google Scholar
• Derakhshani A, Silvestris N, Hemmat N, et al. Targeting TGF-β-mediated SMAD signaling pathway via novel recombinant cytotoxin II: a potent protein from naja naja oxiana venom in melanoma. Molecules. 2020;25(21):5148. doi:10.3390/molecules25215148
   PubMed Web of Science ®Google Scholar
• Chen B, Wang X, Zhang Y, et al. Improved solubility, dissolution rate, and oral bioavailability of main biflavonoids from Selaginella doederleinii extract by amorphous solid dispersion. Drug Delivery. 2020;27(1):309–322. doi:10.1080/10717544.2020.1716876
   PubMed Web of Science ®Google Scholar
• Fei B, Mo Z, Yang J, Wang Z, Li S. Nanodrugs reprogram cancer-associated fibroblasts and normalize tumor vasculatures for sequentially enhancing photodynamic therapy of hepatocellular carcinoma. Int J Nanomed. 2023;18:6379–6391. doi:10.2147/IJN.S429884
   PubMed Web of Science ®Google Scholar
• Li Q, Zhou Y, He W, et al. Platelet-armored nanoplatform to harmonize janus-faced IFN-γ against tumor recurrence and metastasis. J Control Release. 2021;338:33–45. doi:10.1016/j.jconrel.2021.08.020
   PubMed Web of Science ®Google Scholar
• Lin Y, Chen X, Yu C, et al. Radiotherapy-mediated redox homeostasis-controllable nanomedicine for enhanced ferroptosis sensitivity in tumor therapy. Acta Biomater. 2023;159:300–311. doi:10.1016/j.actbio.2023.01.022
   PubMed Web of Science ®Google Scholar
• Gong L, Lu Y, Wang J, et al. Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically. J Pharm Anal. 2023;13(6):603–615. doi:10.1016/j.jpha.2023.04.017
   PubMed Web of Science ®Google Scholar
• Chen B, Wang X, Lin D, et al. Proliposomes for oral delivery of total biflavonoids extract from Selaginella doederleinii: formulation development, optimization, and in vitro-in vivo characterization. Int J Nanomed. 2019;14:6691–6706. doi:10.2147/IJN.S214686
   PubMed Web of Science ®Google Scholar
• Bhattarai RS, Bariwal J, Kumar V, et al. pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma. J Control Release. 2022;350:569–583. doi:10.1016/j.jconrel.2022.08.023
   PubMed Web of Science ®Google Scholar
• Huang S, Zhang Y, Wang L, et al. Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier. J Control Release. 2020;325:10–24. doi:10.1016/j.jconrel.2020.03.049
   PubMed Web of Science ®Google Scholar
• Alrbyawi H, Poudel I, Annaji M, et al. pH-sensitive liposomes for enhanced cellular uptake and cytotoxicity of daunorubicin in melanoma (B16-BL6) cell lines. Pharmaceutics. 2022;14(6):1128. doi:10.3390/pharmaceutics14061128
   PubMed Web of Science ®Google Scholar
• Chen B, Zheng K, Fang S, et al. B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC. J Nanobiotechnol. 2023;21(1):378. doi:10.1186/s12951-023-02078-9
   PubMed Web of Science ®Google Scholar
• Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205–227. doi:10.1080/17425247.2021.1828339
   PubMed Web of Science ®Google Scholar
• Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683 doi:10.1016/j.phrs.2020.104683
   PubMed Web of Science ®Google Scholar
• Zhang C, Shen H, Yang T, et al. A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nat Commun. 2022;13(1):7250. doi:10.1038/s41467-022-34877-3
   PubMed Web of Science ®Google Scholar
• Karras P, Bordeu I, Pozniak J, et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature. 2022;610(7930):190–198. doi:10.1038/s41586-022-05242-7
   PubMed Web of Science ®Google Scholar
• Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599(6):1745–1757. doi:10.1113/JP278810
   PubMed Web of Science ®Google Scholar
• Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2022;9(1):e2103836. doi:10.1002/advs.202103836
   Web of Science ®Google Scholar
• Li R, Xie Y. Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties. J Control Release. 2017;251:49–67. doi:10.1016/j.jconrel.2017.02.020
   PubMed Web of Science ®Google Scholar
• Imtiyaz Z, He J, Leng Q, Agrawal AK, Mixson AJ. pH-sensitive targeting of tumors with chemotherapy-laden nanoparticles: progress and challenges. Pharmaceutics. 2022;14(11):2427. doi:10.3390/pharmaceutics14112427
   PubMed Web of Science ®Google Scholar
• Pontrelli G, Toniolo G, McGinty S, Peri D, Succi S, Chatgilialoglu C. Mathematical modelling of drug delivery from pH-responsive nanocontainers. Comput Biol Med. 2021;131:104238. doi:10.1016/j.compbiomed.2021.104238
   PubMed Web of Science ®Google Scholar
• Kim KS, Kwag DS, Hwang HS, Lee ES, Bae YH. Immense insulin intestinal uptake and lymphatic transport using bile acid conjugated partially uncapped liposome. Mol Pharm. 2018;15(10):4756–4763. doi:10.1021/acs.molpharmaceut.8b00708
   PubMedGoogle Scholar
• Kabil MF, Mahmoud MY, Bakr AF, Zaafar D, El-Sherbiny IM. Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: enhanced in-vitro and in-vivo cytotoxicity. Life Sci. 2022;305:120731. doi:10.1016/j.lfs.2022.120731
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–999. doi:10.2147/IJN.S68861
   PubMed Web of Science ®Google Scholar
• Hiu JJ, Yap MKK. The myth of cobra venom cytotoxin: more than just direct cytolytic actions. Toxicon X. 2022;14:100123. doi:10.1016/j.toxcx.2022.100123
   PubMedGoogle Scholar
• Wu M, Ming W, Tang Y, Zhou S, Kong T, Dong W. The anticancer effect of cytotoxin 1 from Naja atra Cantor venom is mediated by a lysosomal cell death pathway involving lysosomal membrane permeabilization and cathepsin B release. Am J Chin Med. 2013;41(3):643–663. doi:10.1142/S0192415X13500456
   PubMed Web of Science ®Google Scholar
• Pang X, Jiang Y, Xiao Q, Leung AW, Hua H, Xu C. pH-responsive polymer-drug conjugates: design and progress. J Control Release. 2016;222:116–129. doi:10.1016/j.jconrel.2015.12.024
   PubMed Web of Science ®Google Scholar
• Gannimani R, Walvekar P, Naidu VR, Aminabhavi TM, Govender T. Acetal containing polymers as pH-responsive nano-drug delivery systems. J Control Release. 2020;328:736–761. doi:10.1016/j.jconrel.2020.09.044
   PubMed Web of Science ®Google Scholar
• Rezaei N, Mehrnejad F, Vaezi Z, Sedghi M, Asghari SM, Naderi-Manesh H. Encapsulation of an endostatin peptide in liposomes: stability, release, and cytotoxicity study. Colloids Surf B Biointerfaces. 2020;185:110552. doi:10.1016/j.colsurfb.2019.110552
   PubMed Web of Science ®Google Scholar
• Ducat E, Deprez J, Gillet A, et al. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles. Int J Pharm. 2011;420(2):319–332. doi:10.1016/j.ijpharm.2011.08.034
   PubMed Web of Science ®Google Scholar
• Sethuraman V, Janakiraman K, Krishnaswami V, Kandasamy R. Recent progress in stimuli-responsive intelligent nano scale drug delivery systems: a special focus towards pH-sensitive systems. Curr Drug Targets. 2021;22(8):947–966. doi:10.2174/1389450122999210128180058
   PubMed Web of Science ®Google Scholar
• Zhuo S, Zhang F, Yu J, Zhang X, Yang G, Liu X. pH-sensitive biomaterials for drug delivery. Molecules. 2020;25(23):5649. doi:10.3390/molecules25235649
   PubMed Web of Science ®Google Scholar
• Meng Y, Chen J, Liu Y, et al. A highly efficient protein Corona-based proteomic analysis strategy for the discovery of pharmacodynamic biomarkers. J Pharm Anal. 2022;12(6):879–888. doi:10.1016/j.jpha.2022.07.002
   PubMed Web of Science ®Google Scholar
• Han W, Shi L, Xie B, et al. Supramolecular engineering of molecular inhibitors in an adaptive cytotoxic nanoparticle for synergistic cancer therapy. ACS Appl Mater Interfaces. 2020;12(1):1707–1720. doi:10.1021/acsami.9b20178
   PubMed Web of Science ®Google Scholar
• Strijkers GJ, Kluza E, Van Tilborg GA, et al. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis. 2010;13(2):161–173. doi:10.1007/s10456-010-9165-1
   PubMed Web of Science ®Google Scholar
• Lozano N, Al-Ahmady ZS, Beziere NS, Ntziachristos V, Kostarelos K. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent. Int J Pharm. 2015;482(1–2):2–10. doi:10.1016/j.ijpharm.2014.10.045
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang S, Benoit DSW. Degradable poly(ethylene glycol) (PEG)-based hydrogels for spatiotemporal control of siRNA/nanoparticle delivery. J Control Release. 2018;287:58–66. doi:10.1016/j.jconrel.2018.08.002
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.009
   PubMed Web of Science ®Google Scholar
• Nie D, Liu C, Yu M, Jiang X, Wang N, Gan Y. Elasticity regulates nanomaterial transport as delivery vehicles: design, characterization, mechanisms and state of the art. Biomaterials. 2022;291:121879. doi:10.1016/j.biomaterials.2022.121879
   PubMed Web of Science ®Google Scholar
• Al-Joufi FA, Salem-Bekhit MM, Taha EI, et al. Enhancing ocular bioavailability of ciprofloxacin using colloidal lipid-based carrier for the management of post-surgical infection. Molecules. 2022;27(3):733. doi:10.3390/molecules27030733
   PubMed Web of Science ®Google Scholar
• Perez-Potti A, Rodríguez-Pérez M, Polo E, Pelaz B, Del Pino P. Nanoparticle-based immunotherapeutics: from the properties of nanocores to the differential effects of administration routes. Adv Drug Deliv Rev. 2023;197:114829 doi:10.1016/j.addr.2023.114829
   PubMed Web of Science ®Google Scholar
• Shi L, Wang Y, Wang Q, et al. Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts. J Control Release. 2020;324:289–302. doi:10.1016/j.jconrel.2020.05.025
   PubMed Web of Science ®Google Scholar
• Gu Z, Da Silva CG, Hao Y, et al. Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer. J Control Release. 2023;353:490–506. doi:10.1016/j.jconrel.2022.11.049
   PubMed Web of Science ®Google Scholar
• Van Broekhoven CL, Altin JG. A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol. 2001;79(3):274–284. doi:10.1046/j.1440-1711.2001.01010.x
   PubMed Web of Science ®Google Scholar
• Chen KC, Kao PH, Lin SR, Chang LS. The mechanism of cytotoxicity by Naja naja atra cardiotoxin 3 is physically distant from its membrane-damaging effect. Toxicon. 2007;50(6):816–824. doi:10.1016/j.toxicon.2007.06.011
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin LW, Chen ZK, et al. Effects of intratumoral injection of microspheres containing cobra venom cytotoxin on transplanted human hepatoma in nude mice. Zhong Xi Yi Jie He Xue Bao. 2009;7(9):836–841. doi:10.3736/jcim20090908
   PubMedGoogle Scholar
• Guo MP, Wang QC, Liu GF. Pharmacokinetics of cytotoxin from Chinese cobra (Naja naja atra) venom. Toxicon. 1993;31(3):339–343. doi:10.1016/0041-0101(93)90151-8
   PubMed Web of Science ®Google Scholar